If you have spent any time reading about peptides, you have seen BPC-157 and TB-500 sold side by side, usually as a pair. The pairing is so common that many people assume the two are versions of the same thing. They are not.
This article separates them. What each one is, how much published research exists for each, why clinics group them, and where each stands with regulators. We do not describe outcomes, because the published evidence does not support outcome claims for either peptide, and we do not give dosing. For decisions about your own care, talk with a licensed provider.
Two different peptides
BPC-157 is a synthetic peptide. It is the name you see most often in peptide marketing, and it has the larger research footprint of the two.
TB-500 is commonly described as a synthetic fragment related to thymosin beta-4. That distinction matters when you go looking for studies. Research indexed under thymosin beta-4 is not the same body of work as research on the TB-500 fragment, and search results shift a lot depending on which term you use.
Both are investigational peptides. Neither is an approved drug product for the uses people discuss online, which means outcomes are not established and any compounded preparation is a custom preparation rather than a finished product that went through approval. Compounded medications are not FDA approved finished products. A licensed provider determines eligibility. You can read the full Belle safety language.
One more practical difference. Because the two are sold together so often, product listings frequently blur them into a single description, which makes it hard to tell what is actually being claimed about which peptide. Reading them apart is the only way to see how thin the shared evidence base is.
| BPC-157 | TB-500 | |
|---|---|---|
| What it is | A synthetic peptide | Commonly described as a synthetic fragment related to thymosin beta-4 |
| Published results on PubMed (as of September 16, 2026) | 228 results for the search term BPC 157 | 2 results for the search term thymosin beta-4 fragment TB-500 |
| FDA compounding position in the sources cited | Named by FDA among bulk drug substances for compounding that may present significant safety risks | Not addressed in the sources cited here |
| Approved drug status | Investigational, not an approved drug product | Investigational, not an approved drug product |
| Offered by Belle | No | No |
What research exists for each
The cleanest way to compare two investigational peptides is to look at how much has actually been published and indexed. PubMed, run by the National Library of Medicine, is the standard place to check.
As of September 16, 2026, a PubMed search for BPC 157 returned 228 results. On the same date, a PubMed search for thymosin beta-4 fragment TB-500 returned 2 results.
That gap is the single most useful thing to know when someone presents these two peptides as equivalent options. One has a couple hundred indexed entries behind the search term. The other has two.
What a result count does not tell you
A result count is a measure of volume, not of quality, size, design or relevance. A search that returns 228 results includes reviews, letters, commentary and studies of very different types, and it does not tell you whether any of them examined the outcome you personally care about, or whether they studied humans at all.
So treat these numbers the way a clinician would. They tell you how much has been written. They do not tell you that anything works. This article does not describe findings, because doing that responsibly means citing specific studies and stating exactly what each one looked at and reported. That is a conversation for a licensed provider.
- A large result count does not equal proven benefit in people.
- A small result count does not automatically mean a peptide is unsafe, only that very little is indexed under that term.
- Search terms change the answer. Thymosin beta-4 and the thymosin beta-4 fragment are not interchangeable search strings.
- You can run both searches yourself. The links are in the references at the end of this article.
Why clinics pair them
The pairing is a market convention more than a clinical conclusion. A few things drive it.
- They are discussed in the same online communities, where the two names appear together so consistently that the combination became the default way people ask about them.
- Bundles are easier to market as a single system than two separate ingredients are.
None of that is evidence that a combination does more than either peptide alone. The sources cited in this article do not include a study comparing the pair with either peptide by itself, so this article does not imply one exists.
It is also worth naming a pattern that shows up around bundled peptides generally. Products sold in stacks can come with longer ingredient lists, vaguer claims, and less clarity about who evaluated you before shipping. If you are being sold a combination, the questions that matter do not change: which licensed pharmacy prepared it, which licensed provider reviewed your history, and what is the plan if something does not feel right.
Regulatory status
This is where the two peptides look different on paper, though only one of them is addressed in the sources cited here. It is also the main reason availability shifts from year to year and from clinic to clinic.
FDA maintains a category of bulk drug substances for use in compounding that may present significant safety risks. BPC-157 is addressed there. The agency writes:
Compounded drugs containing BPC-157 may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization. FDA has identified no, or only limited, safety-related information for the proposed routes of administration. Therefore, the agency lacks sufficient information to know whether the drug would cause harm when administered to humans.
Read that carefully, because it is precise. FDA is not saying BPC-157 has been shown to cause harm. It is saying there is not enough safety information for the agency to know either way, and it flags two specific technical concerns: immunogenicity for certain routes of administration, and complexities around peptide-related impurities and characterization of the active pharmaceutical ingredient.
For TB-500, the sources cited here do not include an FDA statement, so do not read silence as clearance. The summary is that this article cites no regulatory position on TB-500, and neither peptide is an approved drug product.
What this means if you are shopping
A site that sells you BPC-157 or TB-500 without mentioning any of the above is telling you something about how it operates. The FDA language is public, and a clinic that has read it will usually explain where a substance stands rather than skip the topic.
Belle does not currently offer BPC-157 or TB-500. The peptide and longevity programs Belle does offer, including sermorelin and NAD+, are listed on the longevity treatments page, and each one comes with a provider review before anything is prescribed. Compounded medications at Belle are custom-prepared by licensed compounding pharmacies and are not evaluated by the FDA for safety or effectiveness, which is stated in full in the important safety information.
A few things come up repeatedly when people compare these two. Short answers below, and if your question is about whether something is appropriate for your body or your history, that belongs with a licensed provider. You can see who reviews Belle content and care on the clinical team page, or browse more guides in the Learn hub.
Common questions
Is BPC-157 better than TB-500?
The sources cited in this article cannot answer that. There is more indexed literature under the search term BPC 157, which returned 228 results on PubMed as of September 16, 2026, compared with 2 results for thymosin beta-4 fragment TB-500 on the same date. More published entries is not the same as better results in people.
Are BPC-157 and TB-500 the same peptide?
No. They are two separate compounds. BPC-157 is a synthetic peptide, and TB-500 is commonly described as a synthetic fragment related to thymosin beta-4. They are frequently sold together, which is why people assume they are related products.
Is BPC-157 FDA approved?
No. It is investigational and is not an approved drug product. FDA addresses BPC-157 among bulk drug substances for use in compounding that may present significant safety risks, and states that it lacks sufficient information to know whether the drug would cause harm when administered to humans.
Why is BPC-157 hard to find at legitimate clinics?
The FDA position is a large part of it. The agency has flagged concerns including risk for immunogenicity for certain routes of administration and complexities regarding peptide-related impurities and active pharmaceutical ingredient characterization. Clinics that follow regulatory guidance tend to adjust what they offer accordingly.
Does Belle prescribe BPC-157 or TB-500?
No. Belle does not currently offer either one. The longevity and peptide programs Belle does offer are listed on the longevity treatments page, and every prescription requires review by a licensed provider.
What should I ask before buying a peptide online?
Ask which licensed pharmacy prepares it, whether a licensed provider reviews your medical history before anything ships, what the regulatory status of the substance is, and how to reach a clinician if you have a problem. If a seller cannot answer those four questions clearly, that is your answer.